Chinook Therapeutics is a biopharmaceuticalcompany that develops precision medicines for kidney diseases. It offers atrasentan, a potent and selective endothelin A (ETA) receptor antagonist; zigakibart (BION-1301), is an anti-APRIL monoclonal antibody; and CHK-336, an oral small molecule lactate dehydrogenase (LDHA) inhibitor. The company also conducts research programs in other rare, severe chronic kidney diseases.